| Product vision |
- Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management (TPP-1)
|
| MoA |
- Inhibition of Plasmodium falciparum ACS10/11
|
| Key features |
- Novel mode of action and structure
- Highly potent and active on resistant strains
- Fast killing in vitro and in vivo
- Clean in rat whole embryo culture in vitro
- Low single dose prediction (250mg)
|
| Challenges |
- Low potency on P. vivax and P. knowlesi malaria
- Limited solubility of crystalline material
|
| Status |
|
| Next milestone |
- Good Laboratory Practice (GLP) preclinical studies
|
| Previously |
- Discovery by GSK with support from the Wellcome Trust
- Full reference name is MMV1582367
|
| MMV Project Director |
|
